Other biotechnological approaches include exploiting albumin’s long circulatory half-life to enhance the pharmacokinetics and bio-distribution of drugs, therapeutic proteins and nucleic acids. These molecules are either bound to or fused with albumin. Similarly, albumin nanoparticles that possess the ability not only to transport small molecules but also to enable the controlled release of their bound cargo are currently being developed for in vivo use.
Several of the aspects just mentioned have been dealt with in greater detail in some of the publications mentioned in BOOKS, SPECIAL ISSUE AND REVIEWS.
For news concerning the clinical use of albumin we can also refer you to the website of the Plasma Protein Therapeutics Association: www.pptaglobal.org